Physician profile
Grace Coyle
NPI 1982277968
$3,135.71
in general payments reported to CMS, 2019-2025
29 companies · $302 in 2025
The $302 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $296 · 2022: $991 · 2023: $696 · 2024: $850 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,848.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $1,207.88 | 2023-2025 | Gocovri, Apokyn, Gocovri |
| Avanir Pharmaceuticals, INC. | $432.54 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $383.48 | 2021-2023 | Austedo Xr |
| Amgen INC. | $95.72 | 2021-2023 | Aimovig |
| Supernus Pharmaceuticals, INC. | $92.24 | 2025 | Qelbree |
| Lundbeck LLC | $87.70 | 2022-2023 | Vyepti |
| Otsuka America Pharmaceutical, INC. | $73.04 | 2023 | Nuedexta, Rexulti |
| Neurocrine Biosciences, INC. | $69.43 | 2022-2023 | Ingrezza, Ongentys |
| Sk Life Science, INC. | $68.35 | 2022-2023 | |
| Lilly USA, LLC | $64.01 | 2022-2023 | Reyvow, Emgality |
| Acadia Pharmaceuticals INC | $61.42 | 2022 | |
| Kyowa Kirin, INC. | $60.85 | 2021-2023 | Nourianz |
| Csl Behring | $44.28 | 2022-2023 | Hizentra |
| Biogen, INC. | $43.78 | 2021-2022 | |
| Tanabe Pharma America, INC. | $42.46 | 2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $39.08 | 2022 | |
| Boston Scientific Corporation | $38.10 | 2023 | Watchman Access System |
| Alnylam Pharmaceuticals INC. | $34.73 | 2022-2023 | Onpattro |
| Octapharma USA, INC. | $28.59 | 2023 | Panzyga |
| Biohaven Pharmaceutical Holding Company LTD. | $25.49 | 2022 | |
| Ucb, INC. | $21.59 | 2023 | Briviact |
| Life Molecular Imaging LTD | $18.07 | 2025 | Neuraceq |
| Jazz Pharmaceuticals INC. | $17.49 | 2023 | |
| Corium, LLC | $17.40 | 2023 | Adlarity |
| Biohaven Pharmaceuticals, INC. | $15.42 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.10 | 2022 | |
| Amylyx Pharmaceuticals, INC. | $13.87 | 2023 | Relyvrio |
| Astrazeneca Pharmaceuticals LP | $12.91 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Coyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.